ID   AR230-r
AC   CVCL_DP56
DR   ATCC; CRL-3346
DR   Wikidata; Q54750355
RX   PubMed=10910924;
CC   Population: Japanese.
CC   Doubling time: ~30-48 hours (ATCC=CRL-3346).
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=Mu-BCR transcript (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC=CRL-3346
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8,10
ST   D16S539: 9,13
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 16,20
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9478 ! AR230
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 02-05-24; Version: 11
//
RX   PubMed=10910924; DOI=10.1182/blood.V96.3.1070;
RA   Mahon F.-X., Deininger M.W.N., Schultheis B., Chabrol J., Reiffers J.,
RA   Goldman J.M., Vaz de Melo J.;
RT   "Selection and characterization of BCR-ABL positive cell lines with
RT   differential sensitivity to the tyrosine kinase inhibitor STI571:
RT   diverse mechanisms of resistance.";
RL   Blood 96:1070-1079(2000).
//